Physician profile
Tadele Dinsa
NPI 1902257553
$1,088.92
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $907 · 2022: $182.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $207.44 | 2021-2022 | |
| Pfizer INC. | $199.45 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $135.03 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $109.72 | 2021 | |
| Abbvie INC. | $105.86 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.82 | 2021 | |
| Gilead Sciences, INC. | $80.53 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.04 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $42.93 | 2021 | |
| Cmp Pharma, INC. | $24.05 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.27 | 2021 | |
| Boston Scientific Corporation | $14.57 | 2021 | |
| Philips North America LLC | $14.21 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tadele Dinsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.